Previous 10 | Next 10 |
-- Clinical Development Program of Filgotinib Demonstrated Durable Efficacy Balanced with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks -- Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) announced today the European Medicines...
-- Data Presented at the European League Against Rheumatism, EULAR, European E-Congress of Rheumatology 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced new analyses from two clinical trials evaluating filgotinib, an investig...
Gilead Sciences (NASDAQ: GILD ) and collaboration partner Galapagos NV (NASDAQ: GLPG ) announce week 52 results from two Phase 3 clinical trials, FINCH 1 and FINCH 3 , evaluating JAK1 inhibitor filgotinib in adults with moderately to severely active rheumatoid arthritis (RA). The data a...
-- Integrated Safety Analysis from the Phase 3 FINCH and Phase 2 DARWIN Programs Informs the Long-Term Safety Profile of Filgotinib in RA -- -- Data Presented at the European League Against Rheumatism, EULAR, European E-Congress of Rheumatology 2020 -- Gilead Sciences, Inc. (N...
Gilead Sciences (NASDAQ: GILD ) is one of the largest bio-pharmaceutical companies in the world with a market capitalization of roughly $90 billion. The company has performed admirably well since the start of the year due to investor excitement over Remdesivir, a potential COVID-19 treatment....
Quick Take Pliant Therapeutics ( PLRX ) intends to raise $90 million from the sale of its common stock in an IPO, plus another $10 million in a concurrent private placement, according to an amended registration statement . The company is developing treatments for fibrosis, cancer and othe...
Applied Genetic Reports Positive Preclinical Data for Eye Disorder Treatment Applied Genetic Technologies Corporation (AGTC) announced the results for its clinical trial related to X-Linked retinitis pigmentosa. The data provided the basis for determining the starting dose and the vector...
Background Yesterday, Gilead ( GILD ) and Galapagos ( GLPG ) finally released phase 3 results from their filgotinib trials in ulcerative colitis. Having followed the crowded space for novel ulcerative colitis and Crohn's disease agents very closely for many years, I think the results w...
Gilead Sciences (NASDAQ: GILD) and its collaboration partner, Galapagos (NASDAQ: GLPG) , reported somewhat disappointing news for their anti-inflammatory candidate, filgotinib. The potential blockbuster helped patients with ulcerative colitis achieve remission, but perhaps not as wel...
Gainers: ACB +26.4% . SCVL +5.8% . PGNX +4.4% . EVLO +3.4% . OPRA +3.4% . More news on: Aurora Cannabis Inc., Shoe Carnival, Inc., Progenics Pharmaceuticals, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...